Black Diamond Therapeutics (BDTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors, Shannon Campbell and Kapil Dhingra, both recommended by the board for approval.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve the compensation of named executive officers, with a board recommendation to vote in favor.
Advisory vote on the preferred frequency of future say-on-pay votes, with a recommendation for an annual (1 year) frequency.
Board will consider any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends the election of two Class III directors at the 2026 annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, with board support for approval.
Shareholders are asked to indicate preferred frequency for future say-on-pay votes, with a recommendation for annual votes.
Latest events from Black Diamond Therapeutics
- Silevertinib showed strong Phase 2 efficacy in NSCLC; cash funds operations into late 2028.BDTX
Q2 2026 - All proposals, including director elections and auditor ratification, were approved by stockholders.BDTX
AGM 2026 - Silevertinib shows robust efficacy and CNS activity in non-classical EGFR-mutant NSCLC.BDTX
Jefferies Global Healthcare Conference 2026 - Silevertinib delivers 60% ORR, 86% CNS response, and 15.2m PFS in EGFR NCM NSCLC.BDTX
Study result - Silevertinib demonstrates strong efficacy and CNS activity in NSCLC and GBM, targeting major unmet needs.BDTX
Corporate presentation - Q1 2026 net loss of $9.0M, cash runway into H2 2028, silevertinib Phase 2 trials advance.BDTX
Q1 2026 - Annual meeting covers director elections, auditor ratification, pay, and ESG oversight.BDTX
Proxy filing - Silevertinib shows high efficacy and CNS activity in NSCLC and will advance to phase II GBM trial in 2026.BDTX
Study Update - BDTX-1535 showed 42% ORR and durable, well-tolerated activity in EGFRm NSCLC.BDTX
Study Update